Hi,
moomoo ID:NaN
Log Out
English
Back
Download
Log in to access Online Inquiry
Quotes
Detailed Quotes
Company Overview
Company ProfileCompany Executives
Financial Analysis
Main CompositionKey IndicatorsFinancial Statement
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > NAMSW NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) > Detailed Quotes

NAMSW NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM)

Watchlist
1.390
+0.290+26.36%
Close  01/27 16:00 ET
High
1.510
Open
1.130
Turnover
53.03K
Low
1.130
Pre Close
1.100
Volume
39.90K
Market Cap
0
P/E(TTM)
0.00
52wk High
1.510
Shares
0
P/E(Static)
0.00
52wk Low
0.464
Float Cap
0
Bid/Ask %
-33.33%
Historical High
1.510
Shs Float
0
Volume Ratio
3.39
Historical Low
0.464
Dividend TTM
--
Div Yield TTM
--
P/B
0.00
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.00%
Amplitude
34.55%
Avg Price
1.329
Lot Size
1
Float Cap
0
Bid/Ask %
-33.33%
Historical High
1.510
Shs Float
0
Volume Ratio
3.39
Historical Low
0.464
Dividend TTM
--
P/B
0.00
Dividend LFY
--
Turnover Ratio
0.00%
Amplitude
34.55%
Avg Price
1.329
Lot Size
1
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast

News

Comment

News

Announcement

No More
Company Overview More
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.
CEO： Dr. Michael Harvey Davidson, M.D.
Market： NASDAQ
Listing Date： 12/09/2020
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Get Started
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist